Chief Investigator: Dr David Bloomfield
Principal Investigator for Qualitative Patient/Clinician decision making study: Professor Dame Lesley Fallowfield
QoL Coordinator: Lucy Matthews
Data Manager: Shirley May
Funded by: Myriad Genetics
The use of a prognostic tool (EndoPredict®) to inform adjuvant chemotherapy decisions in low to medium risk oestrogen receptor positive, Her-2 negative early breast cancer: feasibility, acceptability and economic impact in multicentre UK NHS practice.
The primary quantitative aim is the change in decision made by the patient and clinician around chemotherapy as a result of the additional information in the EndoPredict® test. Specifically the overall increase or decrease in chemotherapy use.